15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Vaxcyte Inc. (PCVX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 11,965,991 | $431,014,996 | 5.31% | |
| 2. | D E Shaw D. E. Shaw | 4,290,790 | $154,554,256 | +39% | 0.09% |
| 3. | Kynam Capital Derrick Tang | 3,071,588 | $110,638,600 | 8.24% | |
| 4. | Deep Track Capital David Kroin | 3,000,000 | $108,060,000 | +40% | 3.02% |
| 5. | Eversept Partners Kamran Moghtaderi | 1,421,983 | $51,219,828 | +10% | 3.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 937,500 | $15,000,000.00 | 5,156,553 | 2020-06-16 | Filing | |
| $16.00 | 12,500 | $200,000.00 | 4,168,718 | 2020-06-16 | Filing | |
| $16.00 | 93,000 | $1,488,000.00 | 2,222,967 | 2020-06-16 | Filing | |
| $16.00 | 250,000 | $4,000,000.00 | 2,309,554 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $72.37 | 112 | $8,105.44 | 41,620 | 2025-03-05 | Filing | |
| $71.07 | 2,267 | $161,106.62 | 41,732 | 2025-03-05 | Filing | |
| $70.39 | 2,621 | $184,486.95 | 43,999 | 2025-03-05 | Filing | |
| $73.84 | 2,085 | $153,950.15 | 154,931 | 2025-03-03 | Filing | |
| $73.07 | 5,915 | $432,214.97 | 157,016 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,104,203 | $472,046,873 | 0.22% | |
| 2. | 12,509,933 | $450,607,771 | 0.02% | |
| 3. | 12,320,453 | $443,782,718 | 0.01% | |
| 4. | 9,955,978 | $358,614,332 | 0.01% | |
| 5. | 5,032,771 | $181,280,411 | 0.03% |
News See All
TD Cowen Reiterates “Buy” Rating on Vaxcyte (PCVX) With $50 PT
The analyst cited positive Phase II data from the company’s VAX-24 infant vaccine trials.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks with high potential.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
What Does Wall Street Think About Vaxcyte (PCVX)?
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best strong buy stocks to invest in according to Wall Street. Goldman Sachs initiated coverage of Vaxcyte, Inc.
12 Oversold Growth Stocks to Buy According to Analysts
On September 27, Wharton professor emeritus and WisdomTree senior economist Jeremy Siegel joined CNBC for an interview to discuss the latest PCE report and what the data reveal about the market.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter.
Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD).
Hedge Fund Resource Center Billionaire Hedge Funds
